🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. AVP-786 matching placebo, AVP-786

    Otsuka Beijing Research Institute

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule active

    1 trial

  2. AXS-02

    Axsome Therapeutics

    Osteoarthritis, Knee

    phase 3 small molecule active

    1 trial

  3. AXS-02 (oral zoledronate)

    Axsome Therapeutics

    Complex Regional Pain Syndrome

    phase 3 small molecule active

    1 trial

  4. AXS-05

    Axsome Therapeutics

    Depression

    phase 3 small molecule completed

    1 trial

  5. AXS-05

    Axsome Therapeutics

    Treatment Resistant Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  6. AXS-05

    Axsome Therapeutics

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule completed

    3 trials

  7. AXS-05 (dextromethorphan and bupropion) oral tablets

    Axsome Therapeutics

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  8. AXS-05 (dextromethorphan-bupropion)

    Axsome Therapeutics

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule completed

    2 trials

  9. AXS-07

    Axsome Therapeutics

    Migraine

    phase 3 small molecule completed

    1 trial

  10. AXS-07 (MoSEIC meloxicam and rizatriptan)

    Axsome Therapeutics

    Migraine

    phase 3 small molecule completed

    2 trials

  11. AXS-07 (meloxicam-rizatriptan)

    Axsome Therapeutics

    Migraine

    phase 3 small molecule completed

    1 trial

  12. AXS-12 (Reboxetine)

    Axsome Therapeutics

    Narcolepsy

    phase 3 small molecule completed

    3 trials

  13. AXS-14 (Esreboxetine)

    Axsome Therapeutics

    Fibromyalgia

    phase 3 small molecule active

    1 trial

  14. AZD0120, Bortezomib Hikma 3,5 mg Pulver zur Herstellung einer Injektionslösung, DARZALEX 1800 mg solution for injection, Dexamethason 1,5 mg JENAPHARM®, Kyprolis 10 mg powder for solution for infusion, Dexamethason 0,5 mg JENAPHARM®, Pomalidomide Zentiva 3 mg hard capsules, Pomalidomide Zentiva 2 mg hard capsules, Dexamethason 4 mg JENAPHARM, Kyprolis 30 mg powder for solution for infusion, Pomalidomide Zentiva 1 mg hard capsules, Pomalidomide Zentiva 4 mg hard capsules, Kyprolis 60 mg powder for solution f

    AstraZeneca AB

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  15. AZD0780

    AstraZeneca

    Heterozygous Familial Hypercholesterolaemia

    phase 3 small molecule active

    1 trial

  16. AZD0780 Placebo, AZD0780

    AstraZeneca AB

    Heterozygous familial hypercholesterolaemia

    phase 3 small molecule active

    1 trial

  17. AZD0780, AZD0780 Placebo

    AstraZeneca AB

    Hyperlipidemia, Atherosclerotic cardiovascular disease

    phase 3 small molecule active

    1 trial

  18. AZD0780, AZD0780 placebo

    AstraZeneca AB

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  19. AZVUDINE

    The First People's Hospital of Lianyungang

    Chronic Hepatitis B

    phase 3 small molecule active

    1 trial

  20. Abemaciclib

    United Therapeutics Europe Ltd

    Breast Cancer Female

    phase 3 small molecule active

    1 trial

  21. Abraxane 5 mg/ml powder for dispersion for infusion., Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion, Fluorouracil Accord 50 mg/ml šķīdums injekcijām vai infūzijām, CALCIUM FOLINATE , GEMCITABINE ACCORD 100 mg/ml, solution à diluer pour perfusion, Oxaliplatin Accord 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Ipsen

    Metastatic Pancreatic Adenocarcinoma

    phase 3 small molecule active

    1 trial

  22. Abraxane 5 mg/ml powder for dispersion for infusion., Paclitaxel 6 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, Gemcitabine 38 mg/mL concentrate for solution for infusion

    Gilead Sciences Pty Limited

    PD-L1-negative metastatic triple-negative breast cancer or PD-L1-positive metastatic triple-negative breast cancer previously treated with an anti-PD-(L)1 agent in the curative setting

    phase 3 small molecule active

    1 trial

  23. Aceclidine+Brimonidine combination ophthalmic solution

    LENZ Therapeutics

    Presbyopia

    phase 3 small molecule completed

    6 trials

  24. Aceneuramic Acid Extended-Release Tablets

    Ultragenyx UK Limited

    Hereditary Inclusion Body Myopathy

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources